Giovanni Vennarecci

Giovanni Vennarecci


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2013 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
GVGiovanni Vennarecci
Giovanni Vennarecci
ALAndrea Laurenzi
Andrea Laurenzi
RSRoberto Santoro
Roberto Santoro
MCMarco Colasanti
Marco Colasanti
PLPasquale Lepiane
Pasquale Lepiane
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre

1 August 2014 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
GVGiovanni Vennarecci
Giovanni Vennarecci
ALA. Laurenzi
A. Laurenzi
GSGiovanni Battista Levi Sandri
Giovanni Battista Levi Sandri
ERE. Busi Rizzi
E. Busi Rizzi
MCmassimo cristofaro
massimo cristofaro
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre

1 June 2016 in International Journal of Surgery
Verified
Journal Article
Closed access
GVGiovanni Vennarecci
Giovanni Vennarecci
Gian Luca GraziGian Luca Grazi
Gian Luca Grazi
ISIsabella Sperduti
Isabella Sperduti
ERElisa Busi Rizzi
Elisa Busi Rizzi
EFEmanuele Felli
Emanuele Felli
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre
To report our experience on associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in patients with liver tumors. ALPPS is a surgical technique that allows hepatic resection after rapid liver hypertrophy. Thirteen operations were performed: 8 for hepatocellular carcinoma (HCC) with liver cirrhosis (LC) and 5 for colorectal liver metastases (CRLM, n = 3) and cholangiocarcinoma (CC, n = 2) in normal livers (NL). Of the 11 men (85%), the median age was 60 years (range 36-74). Six (75%) HCC patients had BCLC stage C and 2 (25%) had BCLC stage B disease. The median % future liver remnant (FLR) volume increase was 71.7% in patients with LC and 64.8% in NL (p = 0.44). Twelve patients achieved a sufficient FLR growth after the first stage (92.3% efficacy). Four right trisectorectomies and 9 right hepatectomies were performed. All patients completed the second stage (100% feasibility). R0 resection was achieved in all cases. The 90-day mortality rate was 23.1% (12.5% for HCC patients with LC vs 40% for CRLM and CC patients with NL, p = 0.13). After the first stage the overall morbidity rates were 62.5% and 80% (p = 0.61), whereas after the second stage they were 87.5% and 80% in patients with LC and NL respectively (p = 0.99). At a median follow-up of 15 months (range 1-27), the median DFS was 9 months (CI95% 6-12), and the 1yr-DFS was 42%. The median survival was 25 months (CI95% 10-40), and the 1-yr overall survival was 74%. ALPPS induced a considerable and comparable FLR growth in HCC patients with liver cirrhosis and patients with CRLM and CC with normal liver parenchyma. HCC patients who underwent ALPPS had a high rate of macrovascular tumor involvement. A high rate of R0 resection is expected in properly selected patients.

13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Stavros P. PapadakosStavros P. Papadakos
Stavros P. Papadakos
DFDaniele Ferraro
Daniele Ferraro
GCGabriele Carbone
Gabriele Carbone
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
GVGiovanni Vennarecci
Giovanni Vennarecci
Nikolaos MachairasNikolaos Machairas
Nikolaos Machairas
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. There has been significant progress in understanding the risk factors and epidemiology of HCC during the last few decades, resulting in efficient preventative, diagnostic and treatment strategies. Type 2 diabetes mellitus (T2DM) has been demonstrated to be a major risk factor for developing HCC. Metformin is a widely used hypoglycemic agent for patients with T2DM and has been shown to play a potentially beneficial role in improving the survival of patients with HCC. Experimental and clinical studies evaluating the outcomes of metformin as an antineoplastic drug in the setting of HCC were reviewed. Pre-clinical evidence suggests that metformin may enhance the antitumor effects of immune checkpoint inhibitors (ICIs) and reverse the effector T cells’ exhaustion. However, there is still limited clinical evidence regarding the efficacy of metformin in combination with ICIs for the treatment of HCC. We appraised and analyzed in vitro and animal studies that aimed to elucidate the mechanisms of action of metformin, as well as clinical studies that assessed its impact on the survival of HCC patients.

18 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MMMarcello Di Martino
Marcello Di Martino
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
DFDaniele Ferraro
Daniele Ferraro
MMMarilisa Maniscalco
Marilisa Maniscalco
DPDonatella Pisaniello
Donatella Pisaniello
GVGiovanni Vennarecci
Giovanni Vennarecci
Background: Locoregional therapies (LRTs) are commonly used to increase the number of potential candidates for liver transplantation (LT). The aim of this paper is to assess the outcomes of LRTs prior to LT in patients with hepatocellular carcinoma (HCC) beyond the listing criteria. Methods: In accordance with the PRISMA guidelines, we searched the Medline and Web of Science databases for reports published before May 2021. We included papers assessing adult patients with HCC considered for LT and reporting intention-to-treat (ITT) survival outcomes. Two reviewers independently identified and extracted the data and evaluated the papers. Outcomes analysed were drop-out rate; time on the waiting list; and 1, 3 and 5 year survival after LT and based on an ITT analysis. Results: The literature search yielded 3,106 records, of which 11 papers (1874 patients) met the inclusion criteria. Patients with HCC beyond the listing criteria and successfully downstaged presented a higher drop-out rate (OR 2.05, 95% CI 1.45–2.88, p < 0.001) and a longer time from the initial assessment to LT than those with HCC within the listing criteria (MD 1.93, 95% CI 0.91–2.94, p < 0.001). The 1, 3 and 5 year survival post-LT and based on an ITT analysis did not show significant differences between the two groups. Patients with HCC beyond the listing criteria, successfully downstaged and then transplanted, presented longer 3 year (OR 3.77, 95% CI 1.26–11.32, p = 0.02) and 5 year overall survival (OS) (OR 3.08, 95% CI 1.15–8.23, p = 0.02) in comparison with those that were not submitted to LT. Conclusions: Patients with HCC beyond the listing criteria undergoing downstaging presented a higher drop-out rate in comparison with those with HCC within the listing criteria. However, the two groups did not present significant differences in 1, 3 and 5 year survival rates based on an ITT analysis. Patients with HCC beyond the listing, when successfully downstaged and transplanted, presented longer 3 and 5-year OS in comparison with those who were not transplanted.

1 June 2004 in Journal of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
PDF file
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre
GVGiovanni Vennarecci
Giovanni Vennarecci
ABArianna Boschetto
Arianna Boschetto
RDRichard Douard
Richard Douard
ESEugenio Santoro
Eugenio Santoro